Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Genelux develops oncolytic viral immunotherapies targeting difficult-to-treat solid tumors. Its lead candidate, Olvi-Vec, is a proprietary vaccinia virus designed to selectively kill cancer cells and stimulate immune responses. The company focuses on clinical development, manufacturing, and strategic collaborations, aiming to address high unmet medical needs across multiple cancer types with off-the-shelf, personalized immunotherapies.
This description was generated via AI from an annual report. Updated about 1 year ago.